-

ICU Medical, Inc. (ICUI) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of ICU Medical, Inc. (“ICU Medical” or the “Company”) (NASDAQ: ICUI) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ICU MEDICAL, INC. (ICUI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On April 22, 2025, the FDA published a warning letter issued to ICU Medical stating that the Company had “made multiple changes to the Medfusion Model 4000 Syringe Infusion Pump and CADD Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices.” The warning letter stated the subject pumps were “adulterated” and “misbranded” and noted the Company’s modifications “can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile.”

On this news, ICU Medical’s stock price fell $6.04, or 4.4%, to close at $130.68 per share on April 22, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased ICU Medical securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NASDAQ:ICUI

Release Versions

Contacts

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Landstar System, Inc. (LSTR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Landstar System, Inc. (“Landstar” or the “Company”) (NASDAQ: LSTR) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LANDSTAR (LSTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at...

Deadline Approaching: NET Power Inc. (NPWR) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased NET Power Inc. (“Net Power” or the “Company”) (NYSE: NPWR) securities between June 9, 2023 and March 7, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NET POWER INC. (NPWR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITI...

Deadline Approaching: Ibotta, Inc. (IBTA) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 16, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Ibotta, Inc. (“Ibotta” or the “Company”) (NYSE: IBTA) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s April 2024 initial public offering (the “IPO” or “Offering”). I...
Back to Newsroom